To find an alternative anti-microbial that was safe and efficacious against major bacterial, fungal, cancer and viral human pathogens



Yüklə 5,79 Mb.
tarix27.08.2017
ölçüsü5,79 Mb.



  • AIM

  • To find an alternative anti-microbial that was safe and efficacious against major bacterial, fungal, cancer and viral human pathogens.

  • I turned to nature and started to examine all of the supposed anti-bacterial and anti-fungal natural products that are known to man.

  • Among the candidate compounds was the group known as the Melaleuca family, in particular the groups in this family that are approved Australian TGA listed medicines and USA FDA approved to be used in food.











  • The aerial leaves of the plant are harvested from the plantations and steam distilled to produce the raw material - ‘Melaleuca Oil’.

  • Currently there are 500 tons of this raw material available in Australia and around a further 200 tons in other countries.









The Melaleuca oil undergoes a proprietary process which removes, at low boiling point, unstable and potentially toxic monoterpene components and concentrates the heavier bioactive components within the oil.

  • The Melaleuca oil undergoes a proprietary process which removes, at low boiling point, unstable and potentially toxic monoterpene components and concentrates the heavier bioactive components within the oil.

  • The system operates at low temperature, using inert gas purging under high vacuum extraction and in an enclosed system, to remove the bulk of the unwanted compounds.

  • The process can be controlled precisely and the end product can be made to within a 3% range from batch to batch.



Several name changes have occurred over the years.

  • Several name changes have occurred over the years.

  • * MegaBacTM

  • * M.A.C. – (Melaleuca alternifolia concentrate).

  • * 98 AliveTM is the current commercial name of the product

  • The advantages of this process are:

  • Increased Bioactive & Efficacy (in some cases over 200X)

  • Toxicity decreased by 30% (when compared to the raw Melaleuca oil)



From a toxicology point of view M.A.C has been shown to be safe for humans both as a topical application and oral ingestion.

  • From a toxicology point of view M.A.C has been shown to be safe for humans both as a topical application and oral ingestion.

  • We have undertaken acute, sub-acute, 30 day & 90 day oral ingestion studies (up to 30mg/kg body weight = to 1800mg / 60kg body weight person). (See Acute and Sub-acute Toxicity Studies of MAC and photos of rat organs at this dose level)

  • We have also completed the Phase 1 Clinical trial of M.A.C with 40 healthy volunteers. This trial was to assess any changes to normal body functions with varying dose regimes. Blood and urine analysis was carried out and all were found to be within normal standard levels. Even at elevated dosing (up to 900mg/day). Included with this work is a complete pharmacokinetic study. (See Phase 1 – Clinical Trial of M.A.C)



Three studies in 2005 concluded:

  • Three studies in 2005 concluded:

  • 1) Melaleuca alternifolia oil is non-clastogenic (not mutagenic) in the mouse micronucleus test at dose levels of between 1000mg/kg & 1750mg/kg. (See Micronucleus test of Tea tree)

  • 2) Melaleuca alternifolia oil and its major constituent terpinen-4-ol were found not to be mutagens nor carcinogens using the Salmonella reverse mutation assay technique.

  • (See Mutagenic Potential of Tea tree)

  • 3) M.A.C. was tested at concentrations of between 5-25% for acute dermal toxicity in guinea pigs. There were no ill effects.

  • (See Dermal Acute Toxicity)



Currently Listed and approved by TGA:

  • Currently Listed and approved by TGA:

  • * MAC Immune Health Boost – Aust L 179798

  • * Pain Relief Oil – Aust L 179684

  • In Development / In TGA listing process:



The results of a 2009/2010 study series on the effects of M.A.C on selective cytokine induction and activation of immune cell populations in mice were:

  • The results of a 2009/2010 study series on the effects of M.A.C on selective cytokine induction and activation of immune cell populations in mice were:

  • 1) M.A.C helps promote immune response when administered in doses 200mg- 800mg/(kg body weight).

  • 2) M.A.C increases production of selective acute immune phase response cytokines IL-1, IL-3 & IL-6 but not TNF alpha (inflammatory response).

  • 3) M.A.C promotes significant increases in activation of immune “T” cells particularly CD3+, CD4+ (helper cells), CD8+ (killer cells), CD11b, CD40+, and CD80+ lymphocytes.

  • (See Murine Immune Response)



4) Even the smallest dose of M.A.C (200mg/kilo) in mouse trials promoted increased levels of F4/80 (up to 5 fold) and CD11b+ monocyte/macrophages in peripheral blood.

  • 4) Even the smallest dose of M.A.C (200mg/kilo) in mouse trials promoted increased levels of F4/80 (up to 5 fold) and CD11b+ monocyte/macrophages in peripheral blood.

  • 5) M.A.C does not inhibit LPS-induced immune response in vivo, but rather is able to promote these responses.

  • 6) M.A.C shows a greater capacity to promote established antigenic immune responses and hence, its mode of action is different from LPS/endotoxin.

  • M.A.C does not appear to act as a non-specific immune stimulant/adjuvant.

  • (See Murine Immune Response & Dose Response to Oral MAC reports)

  • Gold Coast Griffith University - Medical Centre Department



  • To establish the fact that M.A.C had antiviral activity we have studied the following encapsulated strains:

  • Corona Virus (SARS group) (See Coronavirus - Viricidal Study)

  • Herpes Simplex 1 and 2 (See HS2 - Viricidal Study)

  • Avian A type H1N1 (swine flu – Sun Yat-sen Medical University)

  • Avian A type H1N1 (so called Spanish flu that killed 50 million people)

  • Avian A type H5N1 (current Bird flu Vietnam Strain)

  • Dengue Fever Virus (all 4 strains) – University of Indonesia Jakarta

  • In all cases we killed these strains “in vitro” and for Dengue patients “in vivo”.

  • Sun Yat-sen University in Southern China is working with us on “in vitro” and “in vivo” studies against H1N1 and H2N3 Avian strains.





















INFLUENZA - VIRAL

  • INFLUENZA - VIRAL

  • In 2005 CSIRO completed “in vitro” trials on live fertile chicken eggs against Avian H5N1 influenza Vietnamese strain ( Bird Flu ).

  • The result was that 10,000,000 viruses were totally killed in four hours using 4% M.A.C. with no embryo damage of the live chicken eggs.

  • Electron microscopic photos also shows complete infected cell destruction. (See H5N1 - CSIRO Study)









  • Upon treatment of H5N1 with 4% M.A.C. for three hours, the ultrastructure of the virus changes.

  • Positive control samples displayed ultrastructure consistent with that described for viruses belonging to the family Orthomyxoviridae

  • (Virus Taxonomy. Eighth Report of the International Committee on Taxonomy of Viruses. Edited by C.M. Fauqet, M.A. Mayo, J. Maniloff, U. Desselberger, L.a. Ball. Elsevier, Academic Press, 2005, p 681-693).

  • The ultrastructure of H5N1 treated as described differed in that the stain penetrated the membrane envelope and the majority of surface projections were absent.

  • The ability of the stain to penetrate a greater proportion (subjective observation) of viruses following treatment may be indicative of disruption to the envelope.



To gain an appreciation of the significance of the above changes it should be noted that the surface membrane incorporates various viral proteins and support the surface projections (which are required for infection of host cells) whilst encompassing the viral nucleic acid (nucleocapsid) which is required for replication.

  • To gain an appreciation of the significance of the above changes it should be noted that the surface membrane incorporates various viral proteins and support the surface projections (which are required for infection of host cells) whilst encompassing the viral nucleic acid (nucleocapsid) which is required for replication.

  • One interpretation of the ultrastructural changes could be the inference that they are consistent with the data in Table 1 which show a substantial rise in viral inactivation when H5N1 is exposed to a 4% concentration of M.A.C. for a contact time of greater than 120 mins.

  • Dr Alex Hyatt BSc(Hons), DipEd, PhD, Senior Principal Research Scientist , Project Leader "Bio-Imaging and Ecohealth“, CSIRO, Geelong.





Organism Melaleuca Oil M.A.C. % efficacy +

  • Organism Melaleuca Oil M.A.C. % efficacy +

  • Staphylocccus auerus 10,000 ppm 50 ppm 200

  • Escherichia coli 4000 ppm 100 ppm 40

  • Klebsiella pneumoniae 2,500 ppm 100 ppm 40

  • Bacillus cereus No kill 100 ppm !

  • Proteus vulgaris 4000 ppm 50 ppm 80

  • Pseudomonas aeruginosa 8000 ppm 900 ppm 9

  • The bacteria challenge level was 107 - (10,000,000 cells per ml)

  • In all 53 other strains were tested against M.A.C. all proving increased efficacy.

  • This work was carried out by Professor Thomas Riley in 2005 at the University of Western Australia Queen Elizabeth II Centre, Biotest Laboratories (TGA & NATA Listed Laboratory) and Queensland Pathology Department, Brisbane.



Organism Number of Strains M.A.C. Kill Level

  • Organism Number of Strains M.A.C. Kill Level

  • MRSA 20 wild strains 150 ppm

  • Acinebacter baumanni 14 wild strains 150 ppm

  • Escherichia coli 10 wild strains 150 ppm

  • Klebsiella pneumoniae 10 wild strains 150 ppm

  • Enterobacter cloacae 6 wild strains 150 ppm

  • Klebsiella oxytoca 2 wild strains 150 ppm

  • E faecium Van A 6 wild strains 150 ppm

  • E faecalis Van B 14 wild strains 150 ppm

  • These results are from the Queensland Gov. Pathology Department’s Library of Antibiotic Resistant Strains Project (2005-06).



  • Since these earlier tests we have challenged and killed over a 100 pathogenic bacterial strains including:

  • Listeria monocytogens Salmonella typhimurium

  • Clostridium difficile Vibro chlorea

  • Yersinia enetrocolitica Legonella sp.

  • Clostridium perfergens

  • Specific work has recently been carried out on Helobacter pylori* suspected of being a causative agent in stomach cancer.

  • Our work has shown that M.A.C will kill both the normal and antibiotic resistant strains of this bacteria.

  • * This work has been carried out by Professor Huan Yao Lei - Dept. of Microbiology & Immunology, College of Medicine, Taiwan National Chey Kuy University, Taiwan



  • In conjunction with Dr Rachel Thomson* we are preparing for clinical trials on Non tuberculosis Mycobacterium lung infections.

  • This follows on from our preliminary studies of specifically aging patients who fail to respond to 1st and 2nd line antibiotic. Patients using M.A.C for over 4 years by nebuliser into the lungs with successful outcomes.

  • *Thoracic Specialist – GreenSlopes Private Hospital, Brisbane





The human cancer cell lines included in the testing:

  • The human cancer cell lines included in the testing:

  • Colon cancer: HCT-116, HT-29, SW480

  • Liver cancer: HepG2, Hep3b, SK-HEP-1

  • Breast cancer: MCF-7, MDA-MB-231, BT-474

  • Gastric cancer: NCI-N87, MGC-803

  • Glioma cancer (a kind of brain cancer): U-87MG, U251, U-118MG

  • Brain cancer: SF126, SF17, SF763

  • Pancreatic cancer: BxPC-3, Panc-1, AsPC-1

  • Prostate cancer: DU145, PC-3

  • Kidney cancer: A498, Caki-1, 786-O



  • Developed by Professor Max Reynolds

  • Joint Managing Director - NeuMedix Biotechnology Pty Ltd

  • Joint Managing Director - NeuMedix Melacon Pty Ltd

  • Director – Australasian Botanical Medicine for Population Health

  • Griffith University - Nathan Campus, Brisbane, Australia

  • For further information please contact Professor Reynolds at

  • E mail professor-reynolds@neumedix-biotech.com

  • m.reynolds@griffith.edu.au

  • Phone Mobile 61 414951010

  • Landline 61 734232721




Yüklə 5,79 Mb.

Dostları ilə paylaş:




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©www.azkurs.org 2020
rəhbərliyinə müraciət

    Ana səhifə